Clinical Trials Sponsored by Gadeta B.V.

Total 1477 results

Pharming Technologies B.V.

Completed

A Study of the Safety and Immunogenicity of Repeated rhC1INH Administration (OPERA)

Hereditary Angioedema | Genetic Disorders

Netherlands, Romania
Pantarhei Oncology B.V.

Completed

Evaluation of Safety and Efficacy of Estetrol in Healthy Men

Prostatic Neoplasms

Netherlands
Disphar International B.V.

Withdrawn

Bioequivalence Study of Gliclazide 120 mg Modified Release Tablets

Comparative Bioavailability

Jordan
Disphar International B.V.

Completed

Study of Teysuno (S-1) Combined With Epirubicin and Oxaliplatin in Patients With Advanced Solid Tumors

Patients With Advanced or Metastatic Solid Tumors
Disphar International B.V.

Withdrawn

Comparative Bioavailability Study of Metformin HCl 1000 mg Granules vs Glucophage 1000 mg Film-coated Tablet

Comparative Bioavailability

Jordan
BBB-Therapeutics B.V.

Terminated

Safety, Pharmacokinetics and Pharmacodynamics Study With 2B3-201 in Healthy Subjects and Multiple Sclerosis(MS) Patients

Multiple Sclerosis | Healthy Volunteers

Netherlands
Pharming Technologies B.V.

Completed

Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema

Genetic Disorders

Netherlands
Pharming Technologies B.V.

Completed

Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema

Hereditary Angioedema | Angioneurotic Edema

Netherlands
Pharming Technologies B.V.

Completed

Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema

Hereditary Angioedema | Genetic Disorders | Angioneurotic Edema

Netherlands, Romania
Janssen-Cilag B.V.

Completed

A Study of the Effectiveness and Safety of Treatment With Epoetin Alfa on Hemoglobin Levels, Red Blood Cell Transfusions, and Quality of Life in Patients With Cancer Receiving Platinum-containing Chemotherapy

Anemia | Neoplasm
Adela, Inc

Recruiting

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease (CAMPERR)

Sarcoma | Lymphoma | Cervical Cancer | Leukemia | Stomach Cancer | Breast Cancer | Head and Neck Cancer | Multiple Myeloma | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Lung Cancer | Prostate Cancer | Brain Cancer | Bladder Cancer | Endometrial Cancer | Thyroid Cancer | Renal Cancer | Hepatobiliary...

United States
AVeta Medical

Completed

Clinical Performance and Safety of the VITA AV Clinical System

Vaginal Atrophy

Georgia
Maastricht University Medical Center
Scelta Mycofriends B.V.; CNC Grondstoffen B.V.

Recruiting

Agaricus Bisporus and Influenza Vaccination Response

Immune Response

Netherlands
Seaborough Life Science B.V.
University of Groningen; Chrono@Work B.V.

Not yet recruiting

PBM Effects on Health and Well-being in Humans

Sleep Deprivation | Circadian Rhythm Disorders
Janssen Vaccines & Prevention B.V.

Terminated

A Study of Various Respiratory Syncytial Virus (RSV) Pre-Fusion (preF)-Based Vaccine Formulations in Adults Aged 60 Years and Older

Respiratory Syncytial Virus-associated Lower Respiratory Tract Disease Prevention

United States
Janssen Vaccines & Prevention B.V.

Completed

A Study of Ad26.COV2.S in Healthy Pregnant Participants (COVID-19) (HORIZON 1)

COVID-19 Prevention

United States, South Africa, Brazil
Janssen Vaccines & Prevention B.V.

Completed

A Study to Evaluate Different Dose Levels of Ad26.COV2.S in Healthy Adolescents From 12 to 17 Years Inclusive (HORIZON 2)

Coronavirus Disease-2019 (COVID-19) Prevention

South Africa, Brazil, Argentina, Mexico, India
Janssen Vaccines & Prevention B.V.

Completed

A Study Evaluating the Immunogenicity of Different Clinical Trial Materials of Ad26.RSV.preF- Based Vaccine in Adults Aged 60 - 75 Years Old

Respiratory Syncytial Virus Prevention

United States
Janssen Vaccines & Prevention B.V.

Completed

A Study of an Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadministration, in Adults Aged 65 Years and Older

Influenza, Human Prevention | Respiratory Syncytial Viruses Prevention

United States
Janssen Vaccines & Prevention B.V.

Completed

A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants

Ebola

United States
Janssen Vaccines & Prevention B.V.

Terminated

A Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-Adjuvanted Clade C gp140 in Preventing Human Immunodeficiency Virus (HIV) -1 Infection in Women in Sub-Saharan Africa

HIV-1

South Africa, Malawi, Mozambique, Zambia, Zimbabwe
Janssen Vaccines & Prevention B.V.

Completed

Safety and Efficacy Study of Vaccine Schedule With Ad26.Mos.HIV and MVA-Mosaic in Human Immunodeficiency Virus (HIV)-Infected Adults

Human Immunodeficiency Virus

Thailand
Janssen Vaccines & Prevention B.V.

Completed

A Study to Evaluate the Safety and Immunogenicity of Seasonal Influenza Vaccine and an Adenovirus Serotype 26- Based Vaccine Encoding for the Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF), With and Without Co-administration, in Adults Aged 60 Years and Older in Stable Health

Healthy

United States
Janssen Vaccines & Prevention B.V.

Completed

A Study to Assess the Safety, Reactogenicity and Immunogenicity of a Trivalent Inactivated Poliovirus Vaccine (IPV) Based on Sabin Strains Compared to Conventional Salk IPV in a 6, 10 and 14 Weeks of Age Immunization Schedule

Healthy

Philippines
Janssen Vaccines & Prevention B.V.

Completed

Safety, Tolerability and Immunogenicity Study of Different Vaccine Schedules With Ad26.Mos.HIV and Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults

Healthy

United States
Medical Enterprises Europe B.V.

Withdrawn

SHTC - EUROPE-1 Synergo Hyperthermia-Chemotherapy by European Urologists' Research Operation Preserving Evolution Study I (SHTC-EUROPE-1)

Neoplasms | Urologic Neoplasms | Urogenital Neoplasms | Neoplasms by Site | Urologic Diseases | Urinary Bladder Diseases | Urinary Bladder Neoplasms
Aveta Biomics, Inc.

Recruiting

Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab

Glioma | Glioblastoma Multiforme

United States
Aveta Biomics, Inc.

Available

Treatment of Recurrent GBM With APG-157 Via Expanded Access

Glioblastoma | Glioblastoma Multiforme
Gedea Biotech AB

Completed

VVC Sampling Study for Analysis Validation

Vulvovaginal Candidiasis

United Kingdom
Galera Therapeutics, Inc.

Terminated

Phase I/II Study of SBRT and GC4711 for Centrally Located or Large NSCLC (GRECO-1)

NSCLC | SBRT | Non-metastatic

United States
Istanbul Galata University

Completed

Cluster Analysis to Identify Metabolic Syndrome Components and Physical Fitness in Patients With Metabolic Syndrome (METS)

Metabolic Syndrome

Turkey
Galera Therapeutics, Inc.

Completed

ROMAN: Phase 3 Trial Investigating the Effects of GC4419 on Radiation Induced Oral Mucositis in Head/Neck Cancer Patients

Oral Mucositis

United States, Puerto Rico, Canada
Galera Therapeutics, Inc.

Completed

Ph 2 Open Label Study of GC4419 to Reduce SOM Associated With Chemoradiotherapy for Head and Neck Cancer

Head and Neck Cancer | Oral Mucositis

Spain, Switzerland, Belgium, Poland, Germany, Czechia
Galera Therapeutics, Inc.

Terminated

A Trial of GC4419 in Patients With Critical Illness Due to COVID-19

Covid19 | SARS-CoV-2 Infection

United States
Galera Therapeutics, Inc.

Completed

A Study of the Effects of GC4419 on Radiation Induced Oral Mucositis in Patients With Head/Neck Cancer

Radiation Induced Oral Mucositis

United States, Canada, Puerto Rico
Galena Biopharma, Inc.

Completed

A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders

Thrombocytosis | Myeloproliferative Neoplasms

United States
Galera Therapeutics, Inc.

Completed

A Phase 1 Dose Escalation Study of GC4419 in Combination With Chemoradiation for Squamous Cell Cancer of the Head & Neck

Squamous Cell Carcinoma of the Oral Cavity | Squamous Cell Carcinoma of the Oropharynx

United States
Galena Biopharma, Inc.

Completed

Observational Registry Study of Quality of Life When Treating BTcP With Abstral (RELIEF)

Quality of Life | Breakthrough Cancer Pain

United States
ATRO Medical B.V.
Avania

Recruiting

AIR (Artificial Implant to Restore the Medial Meniscus Function)2 Clinical Investigation (AIR2)

Knee Injuries and Disorders

Netherlands
Janssen Vaccines & Prevention B.V.

Completed

A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Tetravalent Ad26.Mos4.HIV Along With Either Clade C gp140 Plus Adjuvant OR With a Combination of Mosaic and Clade C gp140 Plus Adjuvant in Healthy HIV Uninfected Adults (IPCAVD-012)

Healthy

United States, Rwanda, Kenya
Janssen Vaccines & Prevention B.V.

Completed

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion (Ad26.RSV.Pre-F) Vaccine in RSV-Seronegative Toddlers 12 to 24 Months of Age

Respiratory Syncytial Virus

Canada, United Kingdom, Spain, Brazil, Sweden, Poland, Australia, Finland
Janssen Vaccines & Prevention B.V.

Completed

A Study of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to 75 Years

Respiratory Syncytial Virus Prevention

United States
Janssen Vaccines & Prevention B.V.

Completed

A Study to Evaluate Dose Levels of Ad26.COV2.S Administered as a Two-dose Schedule in Healthy Adults

COVID-19 Prevention

United States, Germany, Brazil, Poland, South Africa
Janssen Vaccines & Prevention B.V.

Completed

A Study of an Ad26.RSV.preF-based Regimen in the Prevention of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV)-Mediated Lower Respiratory Tract Disease in Adults Aged 65 Years and Older (CYPRESS)

Respiratory Tract Diseases | Respiratory Syncytial Viruses

United States
Janssen Vaccines & Prevention B.V.

Completed

A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults (ENSEMBLE 2)

Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19

United States, United Kingdom, Belgium, Spain, France, Germany, Philippines, Brazil, Colombia, South Africa
Orthox Limited
Avania B.V.

Terminated

FibroFix Cartilage P Knee Implant Study (FFLEX)

Osteoarthritis, Knee

United Kingdom, Hungary
Janssen Vaccines & Prevention B.V.

Completed

An Exploratory Study to Evaluate the Prophylactic Efficacy of a Single Immunization of Ad26.RSV.preF Against Respiratory Syncytial Virus Infection in a Virus Challenge Model in Healthy 18 to 50 Year-old Adults

Healthy

United Kingdom
TripleMed B.V.
Fakkel bvba

Completed

ANEUFIX for Endoleaks Type II (ACP-T5)

Abdominal Aortic Aneurysm

Netherlands
Medical Enterprises Europe B.V.

Withdrawn

RITE-EUROPE (Radiofrequency-Induced Thermochemotherapy Effect-EUROPE)

Bladder Cancer
Janssen Vaccines & Prevention B.V.

Completed

A Safety and Immunogenicity Study of Heterologous and Homologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants

Healthy

United States

3

Subscribe